Blurbs

Analysts Offer Insights on Healthcare Companies: Emergent Biosolutions (EBS), Incyte (INCY) and Harmony Biosciences Holdings (HRMY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Emergent Biosolutions (EBSResearch Report), Incyte (INCYResearch Report) and Harmony Biosciences Holdings (HRMYResearch Report).

Emergent Biosolutions (EBS)

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Emergent Biosolutions today and set a price target of $65.00. The company’s shares closed last Monday at $34.23.

According to TipRanks.com, Nakae is a 4-star analyst with an average return of 6.2% and a 40.4% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Arrowhead Pharmaceuticals, and Better Therapeutics, Inc.

Currently, the analyst consensus on Emergent Biosolutions is a Moderate Buy with an average price target of $49.67.

See Insiders’ Hot Stocks on TipRanks >>

Incyte (INCY)

Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Incyte today and set a price target of $95.00. The company’s shares closed last Monday at $77.40.

According to TipRanks.com, Goldstein is a 2-star analyst with an average return of 0.5% and a 34.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $84.70 average price target, which is a 9.4% upside from current levels. In a report issued on July 28, Wells Fargo also initiated coverage with a Hold rating on the stock with a $76.00 price target.

Harmony Biosciences Holdings (HRMY)

Needham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences Holdings today and set a price target of $60.00. The company’s shares closed last Monday at $49.23.

According to TipRanks.com, Fadia is a 1-star analyst with an average return of -2.6% and a 41.2% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Avadel Pharmaceuticals, and ACADIA Pharmaceuticals.

Harmony Biosciences Holdings has an analyst consensus of Strong Buy, with a price target consensus of $60.25, a 18.8% upside from current levels. In a report issued on July 27, Mizuho Securities also maintained a Buy rating on the stock with a $64.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EBS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos